• Mashup Score: 0
    Optimizing initial therapy of CLL - 7 month(s) ago

    Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the specific considerations for optimizing chronic lymphocytic leukemia (CLL) treatment in patients in the frontline setting. These include age, comorbidities, length of treatment (time-limited or continuous), and access to lines of therapy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      🎥 @DrMDavids of @DanaFarber shares insights into optimizing CLL therapy for patients in the front-line setting - a hot topic at this year’s #iwCLL2023 meeting! Check it out here: 👉https://t.co/CAsNBSmvUL #CLLsm #HemOnc @iwCLL #LeuSM

  • Mashup Score: 0
    A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors by ASTCT Talks - 7 month(s) ago

    In this latest episode of ASTCT Talks, Dr. Rebecca Gonzalez sits down with Dr. Katie Gatwood and Dr. Timothy Porter to kick off National Pharmacy Month by discussing the clinical implications of post-transplant cyclophosphamide (PTCy) use outside of the haploidentical setting. They delve into their respective cancer centers’ primary donor sources for match unrelated donors and the breakdown of conditioning intensity within their hematologic patients. They delve into the future of PTCy discussing the potential for earlier de-escalation of immunosuppressants to limit drug-related toxicities and optimize patient outcomes as well as important supportive care considerations. Despite the exciting prospects, the need for robust prospective data before implementation is emphasized. About Dr. Rebecca Gonzalez Dr. Rebecca Gonzalez (@xnyerin) received her Doctor of Pharmacy degree from the University of Florida College of Pharmacy. She completed her PGY2 Oncology residency at West Virginia Univer

    Source: podcasters.spotify.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      Looking for more #HCT and #celltherapy pharmacy content for #NationalPharmacyWeek? Check out this recent episode of ASTCT Talks, "A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors": https://t.co/pMZti2BKfr @xnyerin https://t.co/PgZ1haE7jn

  • Mashup Score: 0
    Homepage - 7 month(s) ago

    Learn about promising cancer treatments and donate to a cancer research charity to help with efforts to make every cancer patient a survivor.

    Source: standuptocancer.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of SU2C
      SU2C

      Our friends at @MyMyrtleBeach understand the importance of innovative cancer research. So, as @McConaughey says, we can all show up for the moments of a lifetime. Help families make new memories for years to come. ❤️🏖Join our mission at https://t.co/tNxh7nX3VK. #StandUpToCancer https://t.co/sZPXuifldA

  • Mashup Score: 0
    Advice to Duchenne Families - 7 month(s) ago

    Elijah Stacy, author and founder of Destroy Duchenne, gives advice to patients and families dealing with Duchenne muscular dystrophy.

    Source: CheckRare.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CheckRare
      CheckRare

      Elijah Stacy, 22-year-old author of “A Small If” and founder of Destroy Duchenne, gives his advice to patients and families dealing with Duchenne muscular dystrophy #Duchenne #checkrare https://t.co/XrZYeFM00E

  • Mashup Score: 2
    Planned Giving - 7 month(s) ago

    With a planned gift to the American Cancer Society, you can combine your desire to give to charity with your overall financial, tax, and estate planning goals. Find more information on gift planning, bequests, wills, estate planning, legacy, and trusts.

    Source: www.cancer.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AmericanCancer
      AmericanCancer

      Planned Giving is how donors make charitable contributions from financial or estate plans. Nicole Hill from our Planned Giving team explains why these gifts are important. Learn more at: https://t.co/Fn8sLYGVXE  #EstatePlanning https://t.co/chbjRwQVbO

  • Mashup Score: 0
    FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC - The ASCO Post - 7 month(s) ago

    On October 16, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as postsurgical adjuvant treatment, for resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC). Efficacy was evaluated in KEYNOTE-671 (ClinicalTrials.gov identifier NCT03425643), a multicenter, randomized, double-blind, pla cebo-controlled trial in 797 patients with previously

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      .@US_FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC https://t.co/3sUzSwdIMM #LCSM #lungcancer #oncology #Immunotherapy @FDAOncology

Load More